LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe ...

Retrieved on: 2022-09-08 18:25:34

Tags for this article:

Corticosteroids

RTT

Medical specialties

Monoclonal antibodies

Sodium hypochlorite washes

Dupilumab

leo pharma a/s

Click the tags to see associated articles and topics

LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe .... View article details on HISWAI: https://www.valdostadailytimes.com/ap/business/leo-pharma-presents-new-adbrytm-tralokinumab-ldrm-safety-data-in-moderate-to-severe-atopic-dermatitis/article_489f5081-c1d3-5662-a103-85052d7fc8df.html

Excerpt

4. Adbry, a high-affinity human monoclonal antibody, was approved by the U.S. Food and Drug Administration (FDA) in December 2021 for the treatment ...

Article found on: www.valdostadailytimes.com

View Original Article